Lundbeck discontinues phase II study with schizophrenia drug
Following a series of disappointing clinical results, Lundbeck stops a phase II study with compound Lu AF11167 as a treatment for patients with schizophrenia who are experiencing persistent negative symptoms.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.